Screener
Halozyme Therapeutics HALO Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
Based on the most recent quarter.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
FAQ
- What is Halozyme Therapeutics's debt-to-equity?
- Halozyme Therapeutics (HALO) reported debt-to-equity of 15.2× in Q2 2026.
- How has Halozyme Therapeutics's debt-to-equity changed year-over-year?
- Halozyme Therapeutics's debt-to-equity increased by 228.3% year-over-year, from 4.6× to 15.2×.
- What is the long-term trend for Halozyme Therapeutics's debt-to-equity?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's debt-to-equity has grown at a 75.7% compound annual growth rate (CAGR), from 2.7× to 44.6×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Halozyme Therapeutics's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude